Paltusotine

PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Cholelithiasis and Complications of Cholelithiasis
Hyperglycemia and Hypoglycemia
Cardiovascular Abnormalities
Thyroid Function Abnormalities
Steatorrhea and Malabsorption of Dietary Fats
Changes in Vitamin B 12 Levels

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Paltusotine; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/paltusotine
APA 7th: sofidex. (2026, August 3). Paltusotine. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/paltusotine
AMA 11th: Paltusotine. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/paltusotine

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.